22.09.2011 • News

Watson Confirms Amphastar Patent Lawsuit

Generic drug maker Watson Pharmaceuticals Wednesday confirmed that Momenta Pharmaceuticals and Sandoz have filed suit against Amphastar Pharmaceuticals and Watson on September 21 in the US District Court for the District of Massachusetts. Watson and Amphastar intend to vigorously defend the claims in the lawsuit.

The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Momenta's U.S. Patent Nos. 7,790,466 and 7,575,886. Enoxaparin Sodium Injection is a generic equivalent to Sanofi-Aventis' Lovenox.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.